<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Revelation Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/revelation-biosciences-inc</link>
<description>Latest news and press releases for Revelation Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 26 Feb 2026 21:15:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/revelation-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b70378dffbe2df114580.webp</url>
<title>Revelation Biosciences Inc</title>
<link>https://6ix.com/company/revelation-biosciences-inc</link>
</image>
<item>
<title>Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-financial-results-for-the-three-and-twelve-months-ended-december-31-2025</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-financial-results-for-the-three-and-twelve-months-ended-december-31-2025</guid>
<pubDate>Thu, 26 Feb 2026 21:15:00 GMT</pubDate>
<description>SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today reported its financial ...</description>
</item>
<item>
<title>Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-1-145500000</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-1-145500000</guid>
<pubDate>Mon, 26 Jan 2026 14:55:00 GMT</pubDate>
<description>SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement a 1-for-4 reverse split of its common stock. ...</description>
</item>
<item>
<title>Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-exercise-191000035</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-exercise-191000035</guid>
<pubDate>Fri, 23 Jan 2026 19:10:00 GMT</pubDate>
<description>SAN DIEGO, CA / ACCESS Newswire / January 23, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive ...</description>
</item>
<item>
<title>Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-reaches-agreement-fda-133000362</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-reaches-agreement-fda-133000362</guid>
<pubDate>Wed, 21 Jan 2026 13:30:00 GMT</pubDate>
<description>- Single Phase 2/3 Adaptive Study Design - - Clinically Relevant, Objective Composite Endpoint - SAN DIEGO, CA / ACCESS Newswire / January 21, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life ...</description>
</item>
<item>
<title>Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-present-international-140000156</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-present-international-140000156</guid>
<pubDate>Wed, 14 Jan 2026 14:00:00 GMT</pubDate>
<description>- Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ACCESS Newswire / January 14, 2026 / Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage ...</description>
</item>
<item>
<title>Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-reports-inducement-grant-220000481</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-reports-inducement-grant-220000481</guid>
<pubDate>Mon, 12 Jan 2026 22:00:00 GMT</pubDate>
<description>SAN DIEGO, CA / ACCESS Newswire / January 12, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced that on January 8, ...</description>
</item>
<item>
<title>Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-announces-initiation-gmp-140000429</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-announces-initiation-gmp-140000429</guid>
<pubDate>Wed, 07 Jan 2026 14:00:00 GMT</pubDate>
<description>SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced the start of GMP manufacturing ...</description>
</item>
<item>
<title>Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-reached-quorum-december-140000222</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-reached-quorum-december-140000222</guid>
<pubDate>Mon, 01 Dec 2025 14:00:00 GMT</pubDate>
<description>SAN DIEGO, CALIFORNIA / ACCESS Newswire / December 1, 2025 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, today announced it has successfully ...</description>
</item>
<item>
<title>Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-track-end-phase-140000501</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-track-end-phase-140000501</guid>
<pubDate>Thu, 20 Nov 2025 14:00:00 GMT</pubDate>
<description>SAN DIEGO, CA / ACCESS Newswire / November 20, 2025 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced successful submission ...</description>
</item>
<item>
<title>Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-financial-211500449</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-financial-211500449</guid>
<pubDate>Thu, 06 Nov 2025 21:15:00 GMT</pubDate>
<description>SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 6, 2025 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported ...</description>
</item>
<item>
<title>Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-cancellation-130000973</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-cancellation-130000973</guid>
<pubDate>Wed, 29 Oct 2025 13:00:00 GMT</pubDate>
<description>SAN DIEGO, CA / ACCESS Newswire / October 29, 2025 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the October 15, 2025 Special ...</description>
</item>
<item>
<title>Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-adjournment-210000579</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-adjournment-210000579</guid>
<pubDate>Wed, 15 Oct 2025 21:00:00 GMT</pubDate>
<description>SAN DIEGO, CA / ACCESS Newswire / October 15, 2025 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, today announced that the Company as a result ...</description>
</item>
<item>
<title>Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-exercise-123000644</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-exercise-123000644</guid>
<pubDate>Thu, 11 Sep 2025 12:30:00 GMT</pubDate>
<description>SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, announced today the entry into a definitive ...</description>
</item>
<item>
<title>Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-announces-special-webcast-112000946</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-announces-special-webcast-112000946</guid>
<pubDate>Wed, 10 Sep 2025 11:20:00 GMT</pubDate>
<description>- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - Data discussion webcast/conference call will be ...</description>
</item>
<item>
<title>Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/reminder-webcast-conference-call-discuss-205500851</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/reminder-webcast-conference-call-discuss-205500851</guid>
<pubDate>Tue, 09 Sep 2025 20:55:00 GMT</pubDate>
<description>SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 /Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation, wants to remind you of our September 10th ...</description>
</item>
<item>
<title>Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-announces-groundbreaking-top-120000044</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-announces-groundbreaking-top-120000044</guid>
<pubDate>Tue, 09 Sep 2025 12:00:00 GMT</pubDate>
<description>- Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - Data discussion webcast/conference call will be ...</description>
</item>
<item>
<title>Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-financial-103000105</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-financial-103000105</guid>
<pubDate>Fri, 08 Aug 2025 10:30:00 GMT</pubDate>
<description>SAN DIEGO, August 08, 2025--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its financial results for the three and six months ended June 30, 2025.</description>
</item>
<item>
<title>Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA Center for Drug Evaluation and Research</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-congratulates-former-130000695</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-congratulates-former-130000695</guid>
<pubDate>Thu, 24 Jul 2025 13:00:00 GMT</pubDate>
<description>SAN DIEGO, July 24, 2025--Revelation Biosciences, Inc. (Nasdaq: REVB) the "Company" or "Revelation") a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today congratulates its former chairman and shareholder, George Tidmarsh, MD, PhD, who has been selected to head the FDA Center for Drug Evaluation and Research.</description>
</item>
<item>
<title>Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-completes-dosing-130000405</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-completes-dosing-130000405</guid>
<pubDate>Wed, 16 Jul 2025 13:00:00 GMT</pubDate>
<description>SAN DIEGO, July 16, 2025--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, today announced dosing has been completed for the PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered Gemini in patients with Stage 3 and 4 Chronic Kidney Disease (CKD).</description>
</item>
<item>
<title>Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025</title>
<link>https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-1-212600761</link>
<guid isPermaLink="true">https://6ix.com/company/revelation-biosciences-inc/news/revelation-biosciences-inc-announces-1-212600761</guid>
<pubDate>Tue, 01 Jul 2025 21:26:00 GMT</pubDate>
<description>SAN DIEGO, July 01, 2025--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reverse split of its common stock following approval at its Special Meeting of Stockholders held on June 23, 2025. The reverse stock split will be effective as of the morning of July 7, 2025, and the Company’s common stock will trade on a post-split basis at the beginning of trading on the same date under the existing t</description>
</item>
</channel>
</rss>